Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.60 |
| ▸ | DDB1 | Q16531 | 17/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29990479 | 1.00 | CRBN (0.60) | CRBNDDB1POLB | |
| SCHEMBL25074524 | 1.00 | CRBN (0.60) | CRBNDDB1POLB | |
| SCHEMBL30066434 | 1.00 | CRBN (0.60) | CRBNDDB1POLB | |
| SCHEMBL24670590 | 1.00 | CRBN (0.60) | CRBNDDB1POLB | |
| SCHEMBL30778437 | 0.82 | CRBN (0.69) | CRBNDDB1POLB | |
| SCHEMBL25501627 | 0.82 | CRBN (0.69) | CRBNDDB1POLB | |
| SCHEMBL24832965 | 0.82 | CRBN (0.60) | CRBNDDB1POLB | |
| SCHEMBL25500434 | 0.82 | CRBN (0.60) | CRBNDDB1POLB | |
| Hydrochloric Acid SCHEMBL29153107 | 0.81 | CRBN (0.68) | CRBNDDB1POLB | |
| SCHEMBL31102193 | 0.79 | CRBN (0.57) | CRBNDDB1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570662-B2 | Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases | NURIX THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20240417402-A1 | SUBSTITUTED PYRROLO[1,2-b]PYRIDAZINES AS BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES | GILEAD SCIENCES, INC. | 2024-12-19 | — | — | US | disclosed |
| CN-117813307-A | Difunctional degradants of interleukin-1 receptor related kinase and therapeutic uses thereof | 新锐思生物制药股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-117693502-A | Compounds for inhibiting or degrading ITK, compositions comprising the same, methods of making the same, and methods of using the same | 纽力克斯治疗公司 | 2024-03-12 | — | — | CN | disclosed |
| US-20230120619-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | GILEAD SCIENCES, INC. | 2023-04-20 | — | — | US | disclosed |
| WO-2023023255-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | NURIX THERAPEUTICS, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570662-B2 | Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases | IRAK1, IRAK2, IRAK4 | CRBN 2455/4885DDB1 2477/4885POLB 2671/4885 |
| US-20230120619-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | IRAK1, IRAK2, IRAK4 | CRBN 324/4885DDB1 661/4885POLB 3123/4885 |
| US-20240417402-A1 | SUBSTITUTED PYRROLO[1,2-b]PYRIDAZINES AS BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES | IRAK1, IRAK2, IRAK4 | CRBN 296/4885DDB1 635/4885POLB 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.